News
Hims & Hers names Amazon veteran as COO Nader Kabbani, who led the technology giant’s acquisition of PillPack and the launch of Amazon Pharmacy, will take the role at the telehealth firm this month.
Big Pharma hates the telehealth startup. Meme-stock day traders love it. Why CEO Andrew Dudum won’t stop selling GLP-1s, no ...
Fortune’s Jason Del Rey breaks down Prime Day’s biggest winners, surprises, and what the sales reveal about Amazon’s ...
Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo ...
Hims & Hers Health (HIMS -1.19%) is a telehealth company that offers personalized solutions for its customers. And demand has been robust, with subscriptions for its products risi ...
Hims & Hers’ stock price has swung wildly this year. The telehealth company’s public feud with drugmaker Novo Nordisk knocked off a nearly a third of its valuation on Monday.
Hims & Hers Health Inc.’s stock booked record losses Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth ...
Key Points Hims & Hers is an exciting stock in the telehealth sector, but as a growth stock, it’s not for the faint of heart. The digital health landscape is evolving, and investors might need ...
HIMS posted stellar Q1 FY 2025; growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Click here to find out why HIMS stock is a Hold.
Hosted on MSN1mon
Hims & Hers’ stock plunges. Here’s why Wegovy parent ended its ...Hims & Hers’ stock sank 34.6% Monday, its largest one-day loss since the company went public in September 2019. The decline surpassed the stock’s previous record selloff of 25.8% on Feb. 21 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results